Market Cap | 10.50M | P/E | - | EPS this Y | 55.40% | Ern Qtrly Grth | - |
Income | -10.22M | Forward P/E | -0.35 | EPS next Y | 43.90% | 50D Avg Chg | -21.00% |
Sales | - | PEG | -0.02 | EPS past 5Y | - | 200D Avg Chg | -57.00% |
Dividend | N/A | Price/Book | 1.04 | EPS next 5Y | 15.00% | 52W High Chg | -87.00% |
Recommedations | 2.30 | Quick Ratio | 3.59 | Shares Outstanding | 3.26M | 52W Low Chg | 19.00% |
Insider Own | 8.76% | ROA | -74.39% | Shares Float | 2.89M | Beta | 0.58 |
Inst Own | 1.38% | ROE | -134.67% | Shares Shorted/Prior | 73.79K/104.81K | Price | 0.43 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 118,840 | Target Price | 43.00 |
Oper. Margin | - | Earnings Date | Nov 11 | Volume | 160,312 | Change | 1.54% |
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.
HC Wainwright & Co. | Buy | Aug 20, 24 |
HC Wainwright & Co. | Buy | Aug 19, 24 |
HC Wainwright & Co. | Buy | Aug 1, 24 |
HC Wainwright & Co. | Buy | Jun 12, 24 |
HC Wainwright & Co. | Buy | May 13, 24 |
HC Wainwright & Co. | Buy | Apr 25, 24 |
Benchmark | Speculative Buy | Mar 6, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Lin Patrick | Chief Business - Str.. Chief Business - Strategy Off | Jan 31 | Buy | 2.39 | 4,000 | 9,560 | 27,478 | 02/01/24 |
Ng George K | Chief Executive Offi.. Chief Executive Officer | Jan 30 | Buy | 2.7 | 10,000 | 27,000 | 20,000 | 01/31/24 |
Young David | President & CEO President & CEO | Apr 14 | Buy | 0.5499 | 20,000 | 10,998 | 430,424 | 04/14/23 |
Young David | President & CEO President & CEO | Apr 11 | Buy | 0.48 | 60,000 | 28,800 | 410,424 | 04/13/23 |
Lin Patrick | Chief Business - Str.. Chief Business - Strategy Off | May 17 | Buy | 1.5945 | 2,000 | 3,189 | 433,390 | 05/19/22 |
Lin Patrick | Chief Business - Str.. Chief Business - Strategy Off | Apr 06 | Buy | 3.34 | 2,000 | 6,680 | 431,390 | 04/08/22 |
Yorke Justin W | Director Director | Jan 27 | Sell | 3.30 | 1,854 | 6,118 | 532,563 | 01/31/22 |